A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client‐owned dogs with allergic dermatitis

BACKGROUND: Interleukin (IL)‐31 is an important mediator in canine atopic dermatitis (cAD) and also may be dysregulated in other allergic diseases. HYPOTHESIS/OBJECTIVES: To demonstrate the efficacy and safety of lokivetmab (canine anti‐IL‐31 monoclonal antibody) for treatment of pruritus associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Brussel, Leen, Moyaert, Hilde, Escalada, Monica, Mahabir, Sean P., Stegemann, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Hypersensitivity Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519066/
https://www.ncbi.nlm.nih.gov/pubmed/34180084
http://dx.doi.org/10.1111/vde.12984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519066/
https://www.ncbi.nlm.nih.gov/pubmed/34180084
http://dx.doi.org/10.1111/vde.12984

Ejemplares similares